MNKD vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MannKind Corporation presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only stable financial health. There is a severe disconnect between the current market price of $2.74 and the growth-based intrinsic value of $0.14, suggesting the stock is trading at a massive premium. While revenue growth is impressive at 45.8%, the company suffers from negative shareholders' equity (P/B of -16.51) and consistent earnings misses. Bearish insider activity and a 0/100 technical trend further undermine the optimistic analyst target prices.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
MNKD vs MRK: Head-to-Head Comparison
This page compares MannKind Corporation (MNKD) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.